Eloxx Pharmaceuticals, Inc. (ELOX) - 10-K Summary
Business Context and Reporting Period
Company: Eloxx Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal years ended December 31, 2023, 2024, and 2025.
Context: This filing represents the Company's first periodic report with the SEC since November 2023, submitted to regain compliance with Exchange Act reporting obligations following a period of delinquency due to liquidity constraints. The Company is a clinical-stage biopharmaceutical firm focused on developing small molecules to treat genetic diseases caused by nonsense mutations (NMs). Its lead candidate, exaluren, targets Alport syndrome (AS) and Autosomal Dominant Polycystic Kidney Disease (ADPKD). A second candidate, ZKN-013, is being developed in collaboration with Almirall for rare skin diseases.
Key Financial Metrics
| Financial Metric (in thousands) | 2025 | 2024 | 2023 |
|---|---|---|---|
| License and Service Revenue | $0 | $6,359 | $0 |
| Total Operating Expenses | $6,438 | $8,827 | $17,288 |
| Net Loss | $(5,995) | $(3,143) | $(17,054) |
| Cash and Cash Equivalents (Year End) | $4,785 | $111 | $1,134 |
| Accumulated Deficit | $(300,580) | $(294,585) | $(291,442) |
| Debt (Carrying Value) | $1,000 | $6,716 | $3,831 |
Note: 2024 revenue was driven by a $6.4 million milestone and upfront payment from the Almirall License Agreement. No revenue was recognized in 2025 as performance obligations were completed.
Material Changes vs. Prior Period
- Revenue: Revenue dropped to zero in 2025 from $6.4 million in 2024. The 2024 revenue was a one-time event related to the Almirall collaboration; the Company has no other commercial revenue streams.
- Expenses: Total operating expenses decreased by 27% in 2025 ($6.4M) compared to 2024 ($8.8M), and by 49% compared to 2023 ($17.3M). This reduction reflects significant cost-cutting measures, including reduced headcount and lower clinical trial spending.
- Liquidity: Cash balances improved significantly from $111,000 at the end of 2024 to $4.8 million at the end of 2025, primarily due to a PIPE financing transaction with Coastlands Capital Partners and the conversion of debt to equity.
- Debt: Outstanding debt decreased from $6.7 million in 2024 to $1.0 million in 2025. Approximately $8.5 million of debt held by Domicilium was converted into pre-funded warrants in September 2025.
Guidance, Outlook, and Risks
Outlook and Clinical Pipeline:
- Exaluren (NMAS): Plans to initiate a Phase 2b clinical trial in the first half of 2026. Topline data from the initial 16-week placebo-controlled part is anticipated by mid-2027.
- Exaluren (nmADPKD): Plans to initiate a Phase 2 trial in 2027, with topline data expected by mid-2028.
- ZKN-013: Development and commercialization rights were licensed to Almirall. The Company remains eligible for up to $470 million in future milestones and royalties.
Going Concern: The Company has concluded that its cash and cash equivalents as of December 31, 2025, combined with subsequent financing ($5.0M from Coastlands in Feb 2026 and $2.0M from Domicilium in March 2026), are not sufficient to maintain operations for the next twelve months. The independent auditor has expressed substantial doubt regarding the Company's ability to continue as a going concern. Additional capital raises are required to fund the planned Phase 2b trial.
Key Risks:
- Capital Requirements: Failure to raise additional capital could force the Company to delay, reduce, or terminate product development programs.
- Regulatory Compliance: The Company was delinquent in SEC filings from November 2023 until this filing. While it aims to regain compliance and uplist to Nasdaq, there is no assurance of success.
- Internal Controls: Management identified a material weakness in internal control over financial reporting due to inconsistent execution of financial reporting controls during the reporting periods.
- Stock Listing: Common stock is currently traded on the OTC Expert Market following delisting from Nasdaq in October 2023.
Investor Verification Checklist
- Capital Sufficiency: Verify the status of the "Coastlands Third Tranche Closing" and subsequent funding to confirm if the "substantial doubt" regarding going concern has been alleviated.
- SEC Compliance Status: Confirm that the Company has successfully regained full compliance with Exchange Act reporting requirements and is current on all filings.
- Debt Conversion: Review the terms of the debt-to-equity conversions with Domicilium and Coastlands to understand the dilution impact on existing shareholders (approx. 52.5 million pre-funded warrants outstanding as of March 2026).
- Clinical Trial Initiation: Monitor announcements regarding the initiation of the Phase 2b trial for exaluren in NMAS, scheduled for H1 2026.
- Internal Control Remediation: Assess the progress of the remediation plan for the material weakness in internal controls over financial reporting.